The company plans on using the solution as an interventional radiology treatment for men’s prostates, to shrink uterine fibroid tumors and in coordination with chemotherapy. The company will use the solution as a platform for future products. EmboMedics plans to have submitted its first generation device for 510(k) clearance by the end of 2014, according to the report.
More Articles on Supply Chain:
Medline Launches New Products Catalog
Boston Scientific Looks to Expand Chinese Presence
Supply Chain Efficiency Improved With Inventory Management Intervention
